258 related articles for article (PubMed ID: 32459035)
1. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
Sánchez-Rovira P; Hirschberg AL; Gil-Gil M; Bermejo-De Las Heras B; Nieto-Magro C
Oncologist; 2020 Dec; 25(12):e1846-1854. PubMed ID: 32459035
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
[TBL] [Abstract][Full Text] [Related]
3. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
4. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Donders G; Neven P; Moegele M; Lintermans A; Bellen G; Prasauskas V; Grob P; Ortmann O; Buchholz S
Breast Cancer Res Treat; 2014 Jun; 145(2):371-9. PubMed ID: 24718774
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
[TBL] [Abstract][Full Text] [Related]
6. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
Pfeiler G; Glatz C; Königsberg R; Geisendorfer T; Fink-Retter A; Kubista E; Singer CF; Seifert M
Climacteric; 2011 Jun; 14(3):339-44. PubMed ID: 21226657
[TBL] [Abstract][Full Text] [Related]
7. Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors.
Donders G; Bellen G; Neven P; Grob P; Prasauskas V; Buchholz S; Ortmann O
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):2023-8. PubMed ID: 26223323
[TBL] [Abstract][Full Text] [Related]
8. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Buchholz S; Mögele M; Lintermans A; Bellen G; Prasauskas V; Ortmann O; Grob P; Neven P; Donders G
Climacteric; 2015 Apr; 18(2):252-9. PubMed ID: 25427450
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of vaginal atrophy with isoflavone vaginal gel.
Lima SM; Yamada SS; Reis BF; Postigo S; Galvão da Silva MA; Aoki T
Maturitas; 2013 Mar; 74(3):252-8. PubMed ID: 23312487
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
Caruso S; Cianci S; Amore FF; Ventura B; Bambili E; Spadola S; Cianci A
Menopause; 2016 Jan; 23(1):47-54. PubMed ID: 26079974
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial.
Mitchell CM; Reed SD; Diem S; Larson JC; Newton KM; Ensrud KE; LaCroix AZ; Caan B; Guthrie KA
JAMA Intern Med; 2018 May; 178(5):681-690. PubMed ID: 29554173
[TBL] [Abstract][Full Text] [Related]
13. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Stute P
Arch Gynecol Obstet; 2013 Dec; 288(6):1199-201. PubMed ID: 24178484
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Streff A; Chu-Pilli M; Stopeck A; Chalasani P
Support Care Cancer; 2021 Jan; 29(1):187-191. PubMed ID: 32328775
[TBL] [Abstract][Full Text] [Related]
15. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study.
Fernandes T; Pedro AO; Baccaro LF; Costa-Paiva LH
Menopause; 2018 Jun; 25(6):641-647. PubMed ID: 29462095
[TBL] [Abstract][Full Text] [Related]
16. Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Villa P; Tagliaferri V; Amar ID; Cipolla C; Ingravalle F; Scambia G; Ricciardi W; Lanzone A
Gynecol Endocrinol; 2020 Jun; 36(6):535-539. PubMed ID: 31847628
[TBL] [Abstract][Full Text] [Related]
17. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
18. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.
Biglia N; Peano E; Sgandurra P; Moggio G; Panuccio E; Migliardi M; Ravarino N; Ponzone R; Sismondi P
Gynecol Endocrinol; 2010 Jun; 26(6):404-12. PubMed ID: 20196634
[TBL] [Abstract][Full Text] [Related]
19. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.
Kendall A; Dowsett M; Folkerd E; Smith I
Ann Oncol; 2006 Apr; 17(4):584-7. PubMed ID: 16443612
[TBL] [Abstract][Full Text] [Related]
20. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
